Jefferies Financial Group assumed coverage on shares of Checkmate Pharmaceuticals (NASDAQ:INBX) in a research note published on Monday morning, The Fly reports. The firm issued a buy rating and a $30.00 target price on the stock. Jefferies Financial Group also issued estimates for Checkmate Pharmaceuticals’ Q3 2020 earnings at ($0.56) EPS, Q4 2020 earnings at ($0.58) EPS, FY2020 earnings at ($2.42) EPS, FY2021 earnings at ($2.20) EPS, FY2022 earnings at ($2.26) EPS and FY2023 earnings at ($2.50) EPS.

Several other brokerages have also commented on INBX. Evercore ISI began coverage on Checkmate Pharmaceuticals in a report on Monday. They set an outperform rating and a $30.00 price objective for the company. Credit Suisse Group initiated coverage on Checkmate Pharmaceuticals in a report on Monday. They set an outperform rating and a $26.00 price objective for the company.

Shares of INBX opened at $18.43 on Monday. Checkmate Pharmaceuticals has a 12 month low of $15.76 and a 12 month high of $26.98.

In other news, major shareholder Global Investors Lp Viking bought 46,161 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The shares were purchased at an average cost of $19.43 per share, with a total value of $896,908.23. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

About Checkmate Pharmaceuticals

Inhibrx, Inc, a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors.

Further Reading: Accumulation/Distribution

The Fly

Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.